Pharmacogenomics of Drug Transporters

It has now been established that genetic polymorphisms in drug metabolizing enzymes such as the cytochrome P450s (CYP) and the phase II enzyme, thiopu-rine methyltransferase, are responsible for inter-individual variability in response and adverse reactions [12, 13]. However, at the present time, the impact of poly- 

---

Ishikawa, T., Onishi, Y., Hirano, H. et al. (2004). Pharmacogenomics of drug transporters a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDRl). Biol. Pharm. Bull., 27, 939 48. 

Lee VH, Sporty JL, Fandy TE. Pharmacogenomics of drug transporters The next drug delivery challenge. Adv Drug Deliv Rev 2001 50(suppl 1) S33—40. 

Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy... 

Ishikawa T, Tsuji A, Inui K, Sai Y, Airzai N, Wada M et al. The genetic polymorphism of drug transporters Functional analysis approaches. Pharmacogenomics 2004 5 67-99. 

Sparreboom A, Danes R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003 6 71-84. 

Kiyotani K et al (2012) Pharmacogenomics of tamoxifen roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 27(1) 122—131... 

Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002 54 1343-52. 

---